What is Conisus?
Established in 1999 and headquartered in Atlanta, Conisus specializes in delivering tailored strategic medical communication services. The company focuses on critical areas such as brand strategy, business intelligence, and the development of customized educational programs designed to elevate patient care. Conisus serves biopharmaceutical clients by enhancing their brand presence and supporting successful product launches. Their commitment to integrity and exceptional service delivery to healthcare professionals and clients solidifies their role as a key partner in the biopharma ecosystem.
How much funding has Conisus raised?
Conisus has raised a total of $46.5M across 1 funding round:
Debt
$46.5M
Debt (2013): $46.5M with participation from Monroe Capital
Key Investors in Conisus
Monroe Capital
Monroe Capital is a private credit asset management firm specializing in providing financing solutions to middle-market companies. They focus on direct lending, offering senior, unitranche, and junior debt financing, as well as equity co-investments to support businesses through various stages of growth, acquisitions, recapitalizations, and refinancings.
What's next for Conisus?
With a substantial enterprise-level funding history, Conisus is well-positioned for continued growth and innovation in the biopharmaceutical communications landscape. The recent strategic investment signals confidence from its backers in the company's business model and its capacity to navigate the complexities of medical communications, especially in oncology and hematology. Future endeavors will likely involve expanding its service portfolio, deepening its market penetration, and leveraging its expertise to support an increasing number of product launches and brand strategies within the biopharma industry. The company's trajectory suggests a focus on scaling its operations and reinforcing its leadership in providing high-impact strategic solutions.
See full Conisus company page
